VenstraMedical has announced an investment from Highcroft Capital to accelerate development of the company’s next-generation percutaneous ventricular assist device (pVAD), a low-profile, full-flow system designed to provide complete ventricular unloading for patients in cardiogenic shock or undergoing high-risk coronary interventions.
“We’ve been highly impressed with VenstraMedical’s team and technology,” said Peter Eckman, partner at Highcroft Capital. “As a physician-led group, we’re excited to support a system that could transform cardiac care through improved performance, safety, and ease of use.”
VenstraMedical’s pVAD is a catheter-based pump protected by eight issued patents. It can collapse into a 9Fr catheter for minimally invasive insertion and deliver up to 7L/min of cardiac output once deployed, providing full ventricular unloading and haemodynamic stability.
“Support from experienced cardiologists and users of pVAD technology validates our approach and accelerates our path toward clinical trials,” said Martin Cook, co-founder and chief executive officer of VenstraMedical.
The investment follows publication of VenstraMedical’s pre-clinical data in the ASAIO Journal, a presentation at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference (25–28 October, San Francisco, USA), and a US$1 million grant from MTPConnect’s Targeted Translation Research Accelerator (TTRA) under Australia’s Medical Research Future Fund (MRFF).
